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We have studied the mechanism by which an acidic
domain (amino acids 515–583) of the aromatic hydrocar-
bon receptor (AhR) transactivates a target gene. Studies
with glutathione S-transferase fusion proteins demon-
strate that the wild-type acidic domain associates in
vitro with Myb-binding protein 1a, whereas a mutant
domain (F542A, I569A) does not. AhR-defective cells re-
constituted with an AhR containing the wild-type acidic
domain exhibit normal AhR function; however, cells re-
constituted with an AhR containing the mutant acidic
domain do not function normally. Transient transfec-
tion of Myb-binding protein 1a into mouse hepatoma
cells is associated with augmentation of AhR-dependent
gene expression. Such augmentation does not occur
when Myb-binding protein 1a is transfected into AhR-
defective cells that have been reconstituted with an AhR
that lacks the acidic domain. We infer that 1) Myb-bind-
ing protein 1a associates with AhR, thereby enhancing
transactivation, and 2) the presence of AhR’s acidic do-
main is both necessary and sufficient for Myb-binding
protein 1a to increase AhR-dependent gene expression.
The aromatic hydrocarbon receptor (AhR)1 is an intracellular
protein that mediates transcriptional responses to certain
hydrophobic ligands, the most notorious of which is the wide-
spread environmental contaminant 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD, dioxin) (1–4). The liganded AhR
heterodimerizes with a second protein, known as the AhR
nuclear translocator (Arnt), to form a complex that activates
transcription by binding to an enhancer in the vicinity of the
TCDD-responsive target gene (5, 6). Both AhR and Arnt are
prototypical members of the basic helix-loop-helix/Per-Arnt-
Sim class of transcription factors, which regulate gene expression
in response to a variety of environmental and developmental
signals (7–11).
Much of our understanding of AhR/Arnt-dependent tran-
scription stems from analyses of the TCDD-inducible CYP1A1
gene in mouse hepatoma cells; this experimental system ben-
efits from the availability of AhR-defective and Arnt-defective
cells. Efficient reconstitution of such cells by retroviral infec-
tion permits analyses of AhR and Arnt mutants in a relatively
physiological setting (12–14). Studies of CYP1A1 gene regula-
tion in mouse hepatoma cells reveal that exposure to TCDD
leads to the binding of AhR/Arnt to an enhancer upsteam of the
CYP1A1 gene. The C-terminal portion of AhR (which contains
several transactivation domains) communicates the induction
signal to the neighboring promoter, which then assumes a more
accessible chromatin structure and binds general transcription
factors (12, 13). Such observations reveal that the transactiva-
tion domains of AhR facilitate enhancer-promoter communica-
tion by a process that involves changes in the structure of
promoter chromatin and occupancy of promoter binding sites
by the transcriptional machinery.
Here, we have studied AhR-dependent transactivation in
more detail; we have focused on a relatively small (69 amino
acid) domain of AhR that is rich in acidic residues and can
transactivate the native chromosomal CYP1A1 gene (13).
Our observations indicate that this acidic activation domain
(AAD) of AhR associates with a factor previously identified as
Myb-binding protein 1a (Mybbp1a) and that Mybbp1a substan-
tially augments the ability of AhR/Arnt to activate transcrip-
tion. These findings reveal new aspects of AhR and Mybbp1a
function.
EXPERIMENTAL PROCEDURES
Materials—The pGudLuc6.1 vector was provided by Dr. Michael S.
Denison (University of California, Davis, CA); it contains an AhR/Arnt-
dependent enhancer and the mouse mammary tumor virus promoter
upstream of a firefly luciferase reporter gene (15). The QuikChange
Site-Directed Mutagenesis Kit and Pfu DNA polymerase were pur-
chased from Stratagene (La Jolla, CA). The pRL-CMV vector and Dual-
Luciferase Report Assay System were purchased from Promega (Mad-
ison, WI). The retroviral vector pMFG was derived from the Moloney
murine leukemia virus (16). The Phoenix-eco retroviral producer cell
line (17) was provided by Dr. Garry Nolan (Stanford University). The
pGEX-2T vector and glutathione-Sepharose were purchased from Am-
ersham Biosciences. [-32]dCTP (3,000 Ci/mmol) and Renaissance
Chemiluminescence Kit were purchased from PerkinElmer Life Sci-
ences. The RNeasy Kit was from Qiagen (Valencia, CA). Reagents for
SDS-PAGE and silver staining were from Bio-Rad. Hyperfilm MP was
from Amersham Biosciences. Tissue culture reagents were from Life
Invitrogen.
Cell Culture—Wild-type (Hepa1c1c7) and AhR-defective (Taoc1BPrcl)
mouse hepatoma cells were cultured as described previously (18). Phoe-
nix cells were cultured as described previously (17).
Plasmid Construction—Mutations to alanine were made in AhR’s
acidic segment at Phe542 and Ile569 using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s instruc-
tions. Plasmid pGAhR515–583 (13) was as used as a template for the
sense and antisense mutation primers. Mutations were confirmed by
nucleotide sequencing.
Wild-type and mutant pGAhR515–583 plasmids were used as tem-
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plates to PCR amplify sequences encoding AhR amino acids 515–583 for
insertion into pMFGAhR494 (13). Both the forward primer (5-ACTACT-
GCAGCGGCCGCACTCTCTGGCGGCCCCTCAGAG-3) and reverse
primer (5-ACTACTGCAGCGGCCGCTCACAGGGAATCCTGCA-
CGTAGGT-3) contained NotI sites (underlined), and the reverse
primer contained a stop codon (bold). The PCR products were digested
with NotI and subcloned into the internal NotI site (amino acids
492–494) of AhR in plasmid pMFGAhR494.
Wild-type and mutant pGAhR515–593 (13) were also amplified for
insertion into pGEX-2T, an expression plasmid for glutathione S-trans-
ferase fusion proteins. A linker sequence containing a BamHI site was
attached to the forward primer, and the reverse primer was linked to an
EcoRI site. The resulting PCR products were ligated in-frame into
BamHI and EcoRI sites within the polylinker region of pGEX-2T, gen-
erating plasmids pGST-AAD and pGST-mutAAD.
Construction of the expression plasmid for Mybbp1a has been de-
scribed previously (19).
Expression of GST Fusion Proteins and GST Pull-down Assays—GST
fusion proteins were expressed in Escherichia coli by induction with 0.5
mM isopropyl -D-thiogalactopyranoside. Cells were lysed 3 h after
induction by five successive freeze-thaw cycles. After centrifugation, the
lysates were incubated with GST-Sepharose beads (500 l per 500-ml
culture) for 30 min at room temperature. The beads were gently pel-
leted and then washed extensively with phosphate-buffered saline.
Whole-cell extracts were prepared from mouse hepatoma cells as
described previously (20) and were incubated with GST fusion proteins
(10 g) in NETN buffer (20 mM Tris (pH 8), 150 mM NaCl, 1 mM
EDTA, and 0.5% Nonidet P-40) for 1 h at 4 °C with shaking. After the
binding reaction, the beads were washed five times with binding buffer
and then boiled in SDS sample buffer. The solubilized proteins were
fractionated on SDS gels and visualized by silver staining. For protein
sequencing, binding reactions were scaled up 10-fold, fractionated by
SDS-PAGE, and transferred to Immobilon-PSQ for protein microse-
quencing. Protein sequence determination was performed by the Pro-
tein/DNA Technology Center of the Rockefeller University (21, 22).
Transient Transfections—Wild-type or reconstituted AhR-defective
mouse hepatoma cells were plated in 35-mm six-well tissue culture
dishes and incubated overnight. Cells were co-transfected using a po-
lybrene method (23) with 2 g of pGudLuc6.1, 10 ng of pRL-Luc (ex-
pression plasmid for Renilla luciferase, used to control for transfection
efficiency) (Promega), and 0, 0.5, 1.0, 2.5, or 5.0 g of Mybbp1a expres-
sion plasmid. Twenty-four hours after transfection, luciferase activities
were determined using the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions. Light produc-
tion was measured using a Lumat LB 9507 luminometer. All experi-
ments were performed at least three times, and the data are expressed
as mean  S.E.
Retroviral Expression of AhR—Five micrograms of pMFGAhR, pM-
FGAhR494, pMFGAhR494/515–583, and the pMFGAhR494–515-583 mutants
were transfected into the ectotropic packaging cell line, Phoenix, as
described previously (17). Recovery of retroviruses and infection of
AhR-defective mouse hepatoma cells was carried out as described
previously (12).
Analysis of CYP1A1 Gene Expression—Wild-type, AhR-defective, and
reconstituted mouse hepatoma cells were grown to 80% confluence in
100-mm tissue culture dishes and were treated with 1 nM TCDD or 0.1%
Me2SO for 18 h. Total RNA was isolated using RNeasy spin columns
(Qiagen). Total RNA (5 g) was fractionated on 1.2% agarose-2.2 M
formaldehyde gels, transferred to Nytran by capillary blotting in 20 
SSC, and cross-linked to the membrane in a UV Stratalinker 2400
(Stratagene). Blots were hybridized with 32P-labeled CYP1A1 or actin
cDNA overnight at 55 °C using ExpressHyb hybridization solution
(CLONTECH). Blots were washed as described previously (24) and then
autoradiographed with Hyperfilm MP (Amersham Biosciences).
Immunoblotting Analysis—Whole-cell extracts were prepared from
wild-type, AhR-defective, and reconstituted cells as described above.
Forty micrograms of cellular proteins were dissolved in 2 Laemmli
sample buffer (Bio-Rad), fractionated by SDS-PAGE, and transferred to
a polyvinylidene difluoride membrane. Blots were incubated in blocking
buffer (20 mM Tris (pH 7.6), 137 mM NaCl, 0.1% Tween 20 (TBS-T)
containing 5% nonfat milk) overnight at 4 °C. Incubation with primary
antibody (anti-AhR, 1:2000) (25) was carried out for 1 h at room tem-
perature. After several washes in blocking buffer, blots were incubated
with secondary antibody (anti-mouse-HRP, 1:2000) for 1 h at room
temperature. After washing in TBS-T, blots were developed using the
Renaissance Chemiluminescence Kit (PerkinElmer Life Sciences) and
visualized on Hyperfilm MP.
RESULTS
Identification of a Protein That Interacts with AhR’s AAD—
We envision that transactivation by AhR involves protein-pro-
tein interactions that facilitate communication between AhR/
Arnt heterodimers bound at an enhancer and other transcrip-
tion factors that interact with the cognate promoter. To analyze
the mechanism of transactivation in further detail, we used a
GST pull-down technique to identify proteins that bind to the
wild-type AAD but not to a mutant AAD that fails to transac-
tivate. For the mutant AAD, we targeted two hydrophobic
residues in regions previously shown to be important for AAD
function (14). The mutant contains alanine substititions at
Phe542 and Ile569 but is otherwise identical to the wild-type
AAD (aa 515–583). We fused the wild-type or mutant AAD to
AhR’s N-terminal half (aa 1–494) to generate AhR1–494/AAD
and AhR1–494/mutAAD, respectively (Fig. 1A).
To assess the function of the wild-type and mutant con-
structs, we introduced them into AhR-defective cells by retro-
viral infection and used Northern blotting to measure the re-
sponse of the native chromosomal CYP1A1 target gene to
TCDD. Positive and negative control experiments reveal that
reconstitution of AhR-defective cells with full-length AhR re-
stores responsiveness of the CYP1A1 gene to TCDD, whereas
reconstitution with AhR1–494 does not (Fig. 1B). Reconstitution
of AhR-defective cells with the AhR1–494/AAD construct re-
stores TCDD-responsiveness to approximately wild-type levels;
in contrast, cells reconstituted with AhR1–494/mutAAD fail to
respond to TCDD (Fig. 1B). Immunoblotting experiments indi-
cate that both the wild-type and mutant constructs are ex-
pressed at nearly identical levels in the reconstituted cells.
Therefore, the failure of the mutant to transactivate is not due
to underexpression of the mutant protein (data not shown).
These findings extend our previous mutational analysis of
AhR’s AAD (14) by identifying a double point mutation that
FIG. 1. Structure and function of AhR constructs. A, structural
representation of AhR constructs. B, function of AhR constructs. AhR-
defective mouse hepatoma cells were reconstituted by retroviral infec-
tion with the indicated AhR constructs, and the response of the CYP1A1
gene to TCDD (1 nM, 24 h) was measured by Northern blotting.
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abolishes function and provides a useful negative control for
GST pull-down experiments.
We constructed GST fusion proteins containing either the
wild-type or mutated AAD, attached the fusion proteins to
glutathione-Sepharose beads, and allowed the beads to interact
with extracts prepared from mouse hepatoma cells. Interacting
proteins were purified and analyzed by SDS-PAGE and silver
staining. Our findings reveal three proteins, with molecular
masses of about 160, 180, and 200 kDa, that interact with the
GST-AAD fusion protein but not with the GST-mutAAD fusion
protein (Fig. 2A). We isolated enough of the most prominent
(160 kDa) AAD-interacting protein to permit its microse-
quencing; the data revealed that the sequences of two tryptic
peptides were identical to sequences within Mybbp1a, a nu-
clear protein that interacts with c-Myb (19).
We confirmed the identity of the AAD-interacting protein in
immunoblotting experiments using an anti-Mybbp1a antibody.
Our findings indicate the presence of an immunoreactive160-
kDa band in pull-down eluates from GST-AAD, but not in
eluates from GST-mutAAD or GST alone (Fig. 2B). In addition,
the immunoreactive band co-localized with the 160 kDa silver-
stained band in a gel run in parallel (data not shown). To-
gether, these findings imply that Mybbp1a interacts with the
wild-type AAD but not with the mutant AAD. It is notable that
the inability of Mybbp1a to interact with the mutant AAD is
associated with loss of transactivation capability in the mutant
(Fig. 1). This observation tends to implicate Mybbp1a in the
transactivation function of the AAD.
Effect of Mybbp1a on AhR-mediated Gene Expression—The
above findings led us to ask whether Mybbp1a affects the
transactivation capability of AhR’s AAD. To address this issue,
we co-transfected mouse hepatoma cells with increasing
amounts of a Mybbp1a expression vector together with a diox-
in-responsive AhR/Arnt-dependent firefly luciferase reporter
construct (pGudLuc) and measured TCDD-inducible luciferase
activity in the transfected cells. Our findings (Fig. 3) reveal
that transfections with increased amounts of Mybbp1a expres-
sion vector are associated with increased responsiveness of the
reporter gene to TCDD. For example, in cells that contain no
Mybbp1a expression vector, TCDD induces luciferase activity
about 11-fold; in contrast, at the highest level of Mybbp1a
expression vector used, TCDD induces luciferase activity about
56-fold. Thus, in this experimental setting, Mybbp1a can in-
crease the responsiveness of an AhR-dependent gene by (at
least) a factor of five.
The results of the expression studies (Fig. 3), together with
those of the pull-down experiments (Fig. 2), imply that
Mybbp1a influences gene expression via AhR’s AAD. To test
this idea directly, we used retroviral vectors to reconstitute
AhR-defective cells with either AhR1–494/AAD, full-length AhR
(as a positive control), or AhR1–494 (as a negative control), and
we established clonal strains of each reconstituted cell type.
Immunoblotting studies confirmed that expression of the AhR
constructs in each of the reconstituted cell strains is similar to
that of AhR in wild-type cells (data not shown). We then tran-
siently transfected these strains with the AhR/Arnt-dependent
firefly luciferase reporter construct (pGudLuc), to document
that the augmentation of AhR-dependent gene expression by
Mybbp1a requires the AAD. The positive and negative controls
reveal, as expected, that Mybbp1a augments the response of
FIG. 2. Identification of Myb-binding protein 1a as a protein
that associates with the AAD of AhR. A, GST pull-down experi-
ments. The indicated GST-AhR fusion proteins were used to isolate
interacting proteins, which were fractionated by SDS-PAGE and iden-
tified by silver staining. B, immunoblotting. Proteins interacting with
the indicated GST-AhR fusion proteins were fractionated by SDS-
PAGE, transferred to a polyvinylidene difluoride membrane, and iden-
tified by immunoblotting, using anti-Mybbp1a as the primary antibody.
FIG. 3. Increasing Mybbp1a expression augments AhR/Arnt
function. Mouse hepatoma cells were co-transfected with an AhR/Arnt-
dependent firefly luciferase reporter gene, an expression plasmid for
Renilla luciferase (to control for transfection efficiency), and the indi-
cated amounts of a Mybbp1a expression vector. Luciferase activity was
measured in uninduced and TCDD-induced (1 nM, 24 h) cells, and firefly
luciferase activity was normalized to Renilla luciferase activity.
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the reporter gene in cells reconstituted with full-length AhR
but not in cells reconstituted with AhR1–494. Notably, in cells
reconstituted with AhR1–494/AAD, Mybbp1a augments lucifer-
ase expression as effectively as it does in the positive control
cells (Fig. 4). These findings imply that the AAD is both nec-
essary and sufficient for Mybbp1a to augment AhR-dependent
gene expression.
DISCUSSION
To better understand the mechanism by which AhR trans-
activates its target genes, we identified Mybbp1a as a factor
that associates with AhR’s AAD in vitro and augments AhR
function in vivo. Our findings are consistent with previous obser-
vations that Mybbp1a may influence transactivation in other
systems (19). Prior analyses of CYP1A1 gene regulation indicate
that the C-terminal portion of AhR mediates enhancer-promoter
communication, producing an accessible chromatin structure
that facilitates promoter occupancy (12, 13). The findings in this
paper imply that Mybbp1a participates in this process.
We have shown previously that hydrophobic residues that
are clustered in two regions of AhR’s acidic segment are impor-
tant for transactivation function (14). Here, we observe that
mutation of Phe542 and Ile569 within the AAD abolishes not
only its association with Mybbp1a but also its transactivation
capability. These findings imply that hydrophobic forces are im-
portant both for the association between the two proteins and for
transactivation function. Previous studies imply that Mybbp1a
binds to c-Myb and to c-Jun via leucine zipper-like motifs (19, 28).
However, AhR’s AAD does not contain a leucine zipper; therefore,
its association with Mybbp1a must involve a different type of
interaction. This conclusion is consistent with other findings
which imply that Mybbp1a influences Myb-dependent and AhR-
dependent gene regulation by different mechanisms. For exam-
ple, Mybbp1a associates with a negative regulatory domain in
the Myb protein (19). In contrast, we find that Mybbp1a interacts
with a transactivation domain of AhR. Furthermore, overexpres-
sion of Mybbp1a fails to alter Myb-dependent gene expression
(19). In contrast, we find that overexpression of Mybbp1a aug-
ments AhR-dependent transcription. Taken together, these ob-
servations imply that Mybbp1a can utilize several different
molecular mechanisms to influence gene expression.
Our GST pull-down experiments reveal that Mybbp1a can
associate with AhR’s AAD in vitro in the absence of TCDD.
Therefore, we infer that TCDD is not required to induce a
factor(s) that facilitates the Mybbp1a-AhR interaction. The
constitutive interaction observed in vitro may not occur in
intact cells, because, for the most part, the two proteins occupy
different subcellular compartments; the unliganded AhR is
cytoplasmic, while Mybbp1a is found in the nucleolus and in
the nucleoplasm (19). It is conceivable that AhR interacts with
Mybbp1a in the cytoplasm because Mybbp1a exhibits nuclear-
cytoplasmic shuttling.2 However, at any one time, most of the
Mybbp1a is in the nucleus. Because of such compartmentaliza-
tion, we envision that the two proteins do not have an oppor-
tunity to associate in vivo until the AhR enters the nucleus
following exposure of cells to TCDD or another ligand.
Our studies reveal that increased expression of Mybbp1a
substantially augments the response of an AhR/Arnt-depend-
ent reporter gene to TCDD. This observation implies that the
availability of Mybbp1a can be a limiting factor for maximal
AhR/Arnt function. We envision that the restricted availability
of Mybbp1a reflects its localization primarily in the nucleolus
(19). The mechanism by which Mybbp1a augments AhR/Arnt
function remains to be determined. We hypothesize that
Mybbp1a contributes via protein-protein interactions to the
formation of productive transcriptional complexes at AhR/Arnt-
dependent promoters. This process could involve recruitment
and/or stabilization of any of numerous factors that participate
in the transcription of genes in chromatin (29–33). In this
regard, we note that Mybbp1a contains several so-called LCD
motifs, which have been implicated in protein-protein interac-
tions involved in inducible gene expression in other systems
(20, 34–36). Our experiments do not reveal whether Mybbp1a
is essential for AhR/Arnt function; studies in Mybbp1a-defec-
tive cells could address this issue in the future.
Our studies re-emphasize the concept that AhR has a mod-
ular organization and that different domains of AhR subserve
different functions. Our observation that the AAD of AhR can
substitute functionally for the entire C-terminal portion of AhR
(which contains several transactivation domains) suggests that
the C-terminal portion exhibits redundancy with respect to its
transactivation capability. One possible advantage of such re-
dundancy is that it might improve the ability of AhR/Arnt to
communicate with transcriptional promoters that differ in
their cognate binding proteins. In this respect, it is notable that
a second, glutamine-rich transactivation domain within AhR’s
C-terminal portion probably interacts with proteins that are
different from those that interact with the AAD (37, 38). Given
this situation, we speculate that the AAD and the glutamine-
rich domain of AhR preferentially communicate with different
sets of transcriptional promoters. This may be an interesting
area for future research.
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